AbbVie sues HRSA to narrow who counts as a 340B patient
Issue
AbbVie sued HRSA in April 2026 to challenge the 30-year-old 340B patient definition, proposing a four-part test: direct care, a clinical encounter, active care management, and a visit within 12 months. AbbVie singled out a Texas health center whose 340B purchases of its drugs rose 119% from 2021 to 2022.
A win would shrink contract pharmacy and telehealth 340B use.
Key points
- It is the first manufacturer lawsuit to challenge HRSA's 340B patient definition.
- AbbVie proposes a four-part test: direct care, a clinical encounter, active management, and a visit within 12 months.
- After the Supreme Court's Loper Bright ruling ended Chevron deference, HRSA guidance is easier to challenge.
Sources for this story
HFMA / Fierce Pharma / 340B ReportPart of
- 340B drug pricing
AbbVie v. HRSA and the patient definition
Sources for your board packet
This story's source plus 4 related stories and their sources, ready to print for your team or board.
The newsletter is paused right now. Sign up and you will get it when it starts again.
Free. Unlocking the packet subscribes you to Intel Brief. You'll also get a short welcome series and the occasional product update. You'll be subscribed right away, with no confirmation email. Unsubscribe with one click in any issue. If you unsubscribed before, we won't re-add you. We never sell your email. You can open each source above without an email.
FQHC Talent. (2026, April 9). AbbVie sues HRSA to narrow who counts as a 340B patient. Source: HFMA / Fierce Pharma / 340B Report. Retrieved November 22, 2026, from https://www.fqhctalent.com/intel/abbvie-340b-patient-definition-lawsuit